Figure 3.

Examination of the metabolic effects of cixutumumab (A12), a specific antibody leading to internalization and degradation of the insulin like growth factor-1 receptor (IGF-1 R) compared to isotype control in high-fat diet fed mice. Male C57BL/6 J mice were fed a high fat diet for 6-weeks and received 10 mg/Kg cixutumumab or isotype control (IC) every 3 days by intraperitoneal injection for 3 weeks, 21 days after commencing diet: (a) Increased food intake in cixutumumab-treated mice compared to isotype control treated mice (n = 12). (b) Similar water intake in A12-treated mice compared to isotype control treated mice (n = 12). (c) Tendency for increased urine output in cixutumumab-treated mice compared to isotype control treated mice (n = 12). (d) Increased faecal output in cixutumumab-treated mice compared to isotype control-treated mice (n = 12). (e) Increased urinary energy loss per day in cixutumumab-treated mice compared to isotype control-treated mice (n = 12). (f) Increased faecal lipid loss per day in cixutumumab-treated mice compared to isotype control-treated mice (n = 12). (g) Gene expression in epididymal fat pad (EFP) of cixutumumab-treated mice compared to isotype control-treated mice (n = 9–13). (h) Gene expression in brown adipose tissue (BAT) from cixutumumab-treated mice compared to isotype control treated mice (n = 15–20). (i) Gene expression in BAT from cixutumumab-treated mice compared to isotype control-treated mice (n = 11–13). (j) Pparg gene expression was increased in subcutaneous adipose tissue (ScAT) of cixutumumab-treated mice compared to isotype control-treated mice (n = 11–13). Data expressed as mean (SEM),* denotes P < 0.05, n denotes number of mice per group, comparisons made using unpaired student's t test or area under curve (AUC) where indicated.